Phase 2 trial of DS-1062a in pretreated advanced NSCLC with genomic alterations posts no results
Phase 2 trial tests DS-1062a drug for advanced lung cancer with specific genetic changes
A Phase 2 interventional trial evaluated DS-1062a (6.0 mg/kg) in 137 participants with advanced/metastatic NSCLC with actionable genomic alt…
A completed Phase 2 trial tested DS-1062a for advanced lung cancer in 137 people who had already received prior chemotherapy and targeted th…
Capmatinib shows efficacy in Chinese NSCLC patients with MET exon 14 skipping mutations
Could a targeted pill help Chinese patients with a specific lung cancer mutation?
An open-label, multicenter phase II study evaluated capmatinib in 36 Chinese adult patients with advanced NSCLC harboring MET exon 14 skippi…
A targeted pill shrank tumors in Chinese lung cancer patients with a specific MET gene mutation, offering a new treatment option for this ge…
Phase III trial tests TTFields plus standard therapy for stage 4 NSCLC after platinum failure
Can adding electric fields to standard treatment help people with advanced lung cancer?
A prospective, randomized phase III trial in 291 patients with stage 4 NSCLC after platinum progression compared TTFields plus standard ther…
Doctors are testing if adding a wearable electric field device to standard drugs helps people with advanced lung cancer live longer after ch…
VATS lobectomy improves overall survival vs open surgery in early-stage NSCLC
Does a less invasive lung cancer surgery help people live longer? New analysis says yes
An individual patient data meta-analysis of 3 RCTs (n=1185) found VATS lobectomy for early-stage NSCLC was associated with a 21% mortality r…
A new analysis of nearly 1,200 patients shows less invasive lung surgery lowers the risk of death by 21% compared to traditional open surger…
Phase 2 Study: L-SABR Plus Standard Therapy in Metastatic NSCLC Patients
Could Targeted Radiation Therapy Offer Hope for Lung Cancer Patients?
This Phase 2 trial evaluates the addition of liver stereotactic ablative radiotherapy (L-SABR) to standard drug therapy in metastatic NSCLC.
A new trial tests if adding targeted liver radiation to standard drugs helps metastatic lung cancer patients live longer without disease pro…
Research across Cancer
Related studies from across the Cancer family.
Meta-analysis links baseline and dynamic ctDNA to survival in advanced NSCLC
ctDNA in blood predicts survival in advanced lung cancer
This systematic review and meta-analysis of 43 studies found that detectable or elevated baseline plasma ctDNA was associated with worse ove…
A blood test for tumor DNA can predict survival in advanced lung cancer, helping guide treatment decisions.
Guideline-based case report: neoadjuvant alectinib in ALK-rearranged stage IIIB lung cancer
One woman shows how alectinib shrinks lung cancer before surgery
This guideline-based case report describes a 57-year-old woman with ALK-rearranged stage IIIB lung cancer treated with neoadjuvant alectinib…
A single case shows alectinib shrinking lung cancer before surgery. This report offers hope for specific patients but needs more study.
Narrative review outlines multimodal decision-making for EGFR-mutant NSCLC with leptomeningeal metastasis
Doctors outline a pathway for treating lung cancer that spreads to the brain
This narrative review addresses patients with EGFR-mutant non-small cell lung cancer who develop resistance to tyrosine kinase inhibitors an…
This review outlines a clinical pathway to help physicians personalize treatment for lung cancer patients with brain spread.
Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion
One Drug Shrinks Lung Tumors When Others Stop Working
This is a case report and literature review of a 77-year-old female with EGFR-TKI-resistant advanced lung adenocarcinoma and malignant peric…
A 77-year-old woman with advanced lung cancer saw her tumors shrink and dangerous fluid around her heart disappear after trying a new drug c…
Post hoc reanalysis suggests stereotactic radiotherapy may improve local control in medically inoperable Stage I non-small cell lung cancer
New analysis gives hope for early lung cancer patients who cannot have surgery
This post hoc Bayesian reanalysis of the LUSTRE trial evaluated stereotactic radiotherapy versus conventional radiotherapy in medically inop…
A new statistical review suggests a focused radiation approach may better control early lung cancer for patients who cannot undergo surgery.
FDA Approves Enhertu (fam-trastuzumab deruxtecan-nxki) for Multiple HER2-Positive and HER2-Low Cancers
FDA approves Enhertu for several types of HER2 positive cancers.
FDA approved Enhertu for several indications including HER2-positive metastatic breast cancer, HER2-low and HER2-ultralow breast cancer, HER…
The FDA has approved Enhertu for multiple cancers, including breast, lung, stomach, and other solid tumors that have a specific protein call…
Network meta-analysis of anti-PD-1/PD-L1 regimens in advanced non-squamous NSCLC without EGFR or ALK alterations
New drugs beat old ones for advanced lung cancer survival
This systematic review and network meta-analysis evaluated overall survival and progression-free survival across 15 Phase III randomized cli…
New drug combinations show better survival chances for advanced lung cancer patients whether their tumors express PD-L1 or not
Review of IVIG and bronchoscopic interventions for pediatric EBV-SMT in immunodeficiency
A rare lung tumor in a boy with immune issues may need IVIG and bronchoscopic procedures
This case report review describes a 10-year-old boy with congenital immunodeficiency and an Epstein–Barr virus-associated smooth muscle tumo…
A single case report suggests IVIG and bronchoscopic procedures might help a rare lung tumor in children with immune problems, though recurr…
Deep hyperthermia with tislelizumab and chemotherapy in advanced squamous NSCLC
Deep Heat Plus Drug Boosts Lung Cancer Response Rates
This retrospective cohort study of 100 patients with advanced squamous NSCLC evaluated deep hyperthermia combined with tislelizumab and chem…
Adding deep heat to standard lung cancer treatment improved response rates significantly while keeping safety levels the same as standard ch…
Consolidation immunotherapy shows no survival benefit over induction alone in stage III non-small cell lung cancer
Adding immunotherapy after chemo may not help stage III lung cancer
This retrospective cohort study evaluated 196 patients with stage III non-small cell lung cancer across 4 hospitals.
Stage III lung cancer patients saw no clear survival gain when immunotherapy was added after chemo and radiation.
Camrelizumab Associated With Higher Progression Risk Versus Pembrolizumab in Nonsquamous NSCLC Cohort
Sintilimab May Be Safer Lung Cancer Treatment
This retrospective cohort study evaluated 409 patients with stage IIIB-IV non-small cell lung cancer receiving PD-1 inhibitors.
One lung cancer drug may cause fewer serious side effects than others while working just as well, a real-world study suggests.
Modified thin-slab volume rendering improves diagnostic performance for pneumonic-type lung cancer and inflammatory pneumonia
New Imaging Trick Tells Cancer and Pneumonia Apart
This retrospective cohort study evaluated modified thin-slab volume rendering (tsVR) with densitometry-derived thresholds against convention…
Doctors can now tell aggressive lung cancer apart from pneumonia more accurately using a simple tweak to CT scans that highlights subtle dif…
Questions about Extensive-Stage Small-Cell Lung Cancer
How does adding a PD-1 inhibitor to platinum-etoposide improve survival in extensive-stage small-cell lung cancer?
Adding a PD-1 inhibitor to platinum-etoposide improves overall survival by about 26% (HR 0.74) and progression-free survival by about 32% (HR 0.68) in ES-SCLC, based on meta-analyses of phase III trials.
Full answer →Does toripalimab plus anlotinib maintenance show promise for extensive-stage small-cell lung cancer?
Yes, a phase II trial found toripalimab plus anlotinib maintenance after first-line chemo led to median progression-free survival of 8.18 months and overall survival of 23.05 months in ES-SCLC.
Full answer →